RxDoctor Payments Data

Geetha Jeyabalan, MD

Surgery · Pittsburgh, PANPI 1598956310

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.1% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $940 and has fallen 67.4% since, to $306 in 2025.

$3,549in general payments, 2019–2025

Across 63 payments — averaging $56.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$844
  • Medtronic$819
  • Cook Medical LLC$577
  • Silk Road Medical, Inc.$431
  • Penumbra, Inc.$369
  • Smith+Nephew$214
  • plus $296 from 7 others
$30,821in research payments, 2019–2025

Across 10 payments — averaging $3082.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$30K
  • C. R. Bard, Inc. & Subsidiaries$1K

What the payments were for

  • Travel & lodging$2096%
  • Food & beverage$3,34094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,549 in reported general payments places this provider in the 70th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$534,174
Medicare patients
1,163
Services billed
3,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate145$1,828
Cilostazol13$506
Atorvastatin Calcium13$350

Paid to pharmacies, not to this prescriber.

Other surgery in Pittsburgh

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →